The ex vivo effect of bitter, sweet, salt, umami and sour tastants on the release of gastrointestinal satiety peptides

Recruitment & Eligibility

Status: Pending

Sex: Not specified

Target Recruitment: 80

Inclusion Criteria

3.1.2 Inclusion criteria for first part of study (duodenal biopsies):
- Step 1 (patients asked for participation):
1) Patients (male and female between 18 and 65 years) referred for upper GI endoscopy (because of functional complaints)
1)2) Based on medical history and previous examination, no objection arises for taking extra biopsies during the gastroduodenoscopy. or colonoscopy.
- Step 2 (patients agreed to participate and in who biopsies will be taken)
1) Patients with no relevant endoscopic abnormalities (gastroduodenoscopy): patients without gastric or duodenal ulcers/polyps/lesions suspect for malignancy and esophageal lesions or varices.;2) Based on medical history and previous examination, no objection arises for taking extra biopsies during the colonoscopy
- Step 2 (patients agreed to participate and in who biopsies will be taken)
2) Patients with no relevant endoscopic abnormalities (colonoscopy): patients without ileal and/or colonic ulcers/polyps/diverticula and lesions suspect for malignancy

Exclusion Criteria

1) History of severe cardiovascular, gastrointestinal/ hepatic, hematological/immunologic, metabolic/nutritional disease and/or laboratory assessments which might limit participation in the study. The severity of the disease (major interference with the execution of the experiment or potential influence on the study outcomes) will be decided by the principal investigator.
2) Use of medication, which could interfere with normal coagulation (anticoagulants, antiplatelet drugs).
3) Major abdominal surgery interfering with gastrointestinal function (uncomplicated appendectomy, cholecystectomy and hysterectomy allowed, and other surgery upon judgement of the principle investigator)
4) Excessive alcohol consumption (>20 alcoholic consumptions per week)

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Main study parameters/endpoints<br /><br>- Measurements in serosal samples of the gut hormones Cholecystokinin (CCK),<br /><br>Glucagon Like Peptide-1 (GLP-1) and Peptide YY (PYY) (in pmol/mL) from human<br /><br>duodenal biopsies in the Ussing chamber<br /><br><br /><br>- Measurements in serosal samples of the gut hormones Cholecystokinin (CCK),<br /><br>Glucagon Like Peptide-1 (GLP-1) and Peptide YY (PYY) (in pmol/mL) from human<br /><br>ileal biopsies in the Ussing chamber</p><br>

Secondary Outcome Measures